博思清与利培酮治疗首发精神分裂症的对照研究

A Controlled Study of Aripiprazole and Risperidone in Treatment of First-episode Schizophrenia.

目的比较博思清和利培酮治疗首发精神分裂症的临床疗效与安全性。方法60例首发住院的女性精神分裂症患者,随机分为两组,分别用博思清和利培酮进行8周治疗。采用阳性症状与阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应。结果两种药物对首发精神分裂症的疗效相当。两组患者在嗜睡、锥体外系症状及月经功能紊乱方面的不良反应差异有显著性(P<0.05)。结论博思清、利培酮对精神分裂症疗效相似,不良反应有所不同,程度均较轻。

Objective To observe the efficacy and safety of aripiprazole and risperidone in the treatment of first-episode schizophrenia. Methods 60 women patients with schizophrenia were included in this 8 weeks opened clinical study. The Positive and Negative Syndrome Scale （PANSS） derived from the PANSS were used to assess the clinical efficacy, the Treatment Emergent Side Effect Scale （TESS） were used to assess the side effects. Results Aripiprazole and risperidone showed good effect on the positive, negative as well as general psychopathological symptoms of schizophrenia. Significant difference existed in the common side effects included drowsiness, weight gain, EPS and menstrual disorder. Conclusion Aripiprazole and risperidone are effective against the positive and negative symptoms of schizophrenia with significantly fewer side effects.